基于分形维数量化肿瘤异质性预测三阴性乳腺癌新辅助化疗反应
回顾性纳入2012年1月至2021年9月在本机构接受新辅助化疗后手术的三阴性乳腺癌患者122例,于治疗前增强MRI勾画病灶ROI并以盒计数法计算分形维数评估瘤内异质性,结合临床病理变量构建预测模型;病理完全缓解率为28.7%(35/122),联合模型预测病理完全缓解的AUC达0.895。
要点
- 治疗前增强MRI病灶分形维数可无创量化三阴性乳腺癌瘤内异质性。
- 联合分形维数与临床数据的模型预测病理完全缓解AUC为0.895,优于临床模型0.846和分形维数模型0.867。
- 多因素分析中肿瘤T分期(OR=1.595)与新辅助化疗前后Ki-67变化(OR=0.099)为病理完全缓解的独立预测因子。
核心结论
- 治疗前MRI获得的分形维数可量化瘤内异质性,是预测三阴性乳腺癌新辅助化疗反应的无创影像生物标志物,联合分形维数与临床数据的模型进一步提高预测准确性。
研究设计与样本
- 回顾性研究,纳入2012年1月至2021年9月在本机构接受新辅助化疗后手术的三阴性乳腺癌患者122例,基于治疗前增强乳腺MRI勾画病灶ROI并以盒计数法行分形维数分析,以术后病理标本分为病理完全缓解组与非病理完全缓解组。
诊断标准与关键数值
- 病理完全缓解定义为术后病理标本评估;多因素回归显示肿瘤T分期OR=1.595(95%CI 1.032-2.467,p=0.036)、新辅助化疗前后Ki-67变化OR=0.099(95%CI 0.044-0.227,p<0.001)、治疗前分形维数校正OR=18.032(95%CI 0.749-434.041,p=0.075)为病理完全缓解的独立预测因子;测试集中临床模型(基于T分期与Ki-67变化)AUC为0.846,分形维数模型AUC为0.867,联合模型AUC为0.895。
临床应用与阅片要点
- 作者认为治疗前增强MRI分形维数可作为量化瘤内异质性的无创影像生物标志物,联合分形维数与临床数据的模型可提高对新辅助化疗病理完全缓解的预测准确性。
局限性
- 治疗前分形维数的校正OR为18.032,95%CI为0.749-434.041,p=0.075,未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Triple-negative breast cancer (TNBC) exhibits high heterogeneity, leading to variable responses to neoadjuvant chemotherapy (NAC) among patients. Noninvasive quantification of intratumoral heterogeneity (ITH) may be valuable in predicting treatment response. This study aims to investigate whether fractal dimension (FD) based on pre-treatment contrast-enhanced magnetic resonance imaging (MRI), combined with clinicopathological data, can predict NAC response in TNBC patients.
METHODS: We retrospectively collected clinicopathological data and pre-treatment contrast-enhanced breast MRI scans of TNBC patients who underwent NAC followed by surgery at our institution from January 2012 to September 2021. Patients were classified into a pathological complete response (pCR) group and a non-pCR group based on postoperative pathological specimens. Regions of interest (ROIs) were delineated on enhanced MRI lesions, and FD analysis was performed using the box-counting method to assess ITH. Univariate and multivariate regression analyses were used to identify variables associated with pCR. A predictive model incorporating relevant clinicopathological variables and FD was constructed, and model performance was evaluated using the area under the ROI curve (AUC).
RESULTS: Among 122 evaluated TNBC patients, 28.7 % (n = 35/122) achieved pCR. Multivariate regression analysis identified tumor T stage (OR = 1.595, 95 %CI:1.032-2.467, p = 0.036), changes in Ki-67 before and after NAC (OR = 0.099, 95 %CI:0.044-0.227, p < 0.001), and pre-treatment FD (adjusted OR = 18.032, 95 %CI:0.749-434.041, p = 0.075) as independent predictors of pCR. In the test set, the AUC of the clinical model based on T stage and Ki-67 changes was 0.846, while the FD model achieved an AUC of 0.867. The combined model, which integrated clinical data with FD, further improved predictive performance, reaching an AUC of 0.895.
CONCLUSION: FD derived from pre-treatment MRI can quantify ITH and serves as a noninvasive imaging biomarker. The combined model integrating FD with clinical data further enhances predictive accuracy.
引用
- Guo J, Liu Y, Ren W, et al. Quantification of tumor heterogeneity based on fractal dimension for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Radiol. 2025. PMID: 40945207. doi:10.1016/j.ejrad.2025.112413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。